June 13 Eli Lilly and Co said on
Thursday it was halting a midstage clinical trial of an
experimental Alzheimer's disease treatment due to potential
liver toxicity problems.
It was the latest setback in the quest to find a treatment
that can slow or cure the memory-robbing condition.
Lilly said the Phase II study of the drug, LY2886721, from a
class known as beta secretase, or BACE, inhibitors, was stopped
after safety monitors identified cases of abnormal liver
Based on the information Lilly has today, it believes that
the abnormal liver biochemical tests observed in this study are
not related to the BACE mechanism and continues to be interested
in developing BACE inhibitors for the benefit of patients with
Alzheimer's disease, the company said.
Lilly said it will continue to monitor all study
participants who were found to have abnormal liver biochemical